Date: Aug 20, 2013 Source: (
click here to go to the source)
Bioptigen Inc. introduced today the ES100, a mounting attachment that enables users of the handheld Bioptigen Envisu™ C2300 spectral domain ophthalmic imaging system to benefit from the mechanical controls of popular operating microscopes. The ES100 mounts to the undercarriage of Zeiss and Leica microscope heads, providing a secure and stable mount when hand held imaging is not desired. With the ES100, clinicians can efficiently target areas of interest, and reduce motion artifacts when maximum stability is the objective. The attachment is at right-angle to a dovetail channel that preserves the mounting capabilities of surgical retinal imaging lenses, such as the Oculus BIOM and the Volk Merlin, thereby offering a mounted OCT imaging solution that does not interfere with present surgical imaging practice.
"The importance of the ES100 attachment is that it provides a stabilized mounting solution for OCT in the operating room that minimizes disruptions to surgical procedures, while offering all of the flexibility and imaging performance of the Envisu C2300″, said Dr. Eric Buckland, CEO of Bioptigen. "The addition of a stable, microscope-mounted option enables exquisite OCT imaging of both anterior and posterior structures in the operating room when handheld imaging is not desired."
The Envisu C2300 SDOIS is FDA cleared for use in upright or supine imaging, handheld or mounted, and for imaging patients under anesthesia.
The ES100 Surgical Mount and the Envisu C2300 SDOIS are being demonstrated at the Optical Tomography and Imaging: Panel Experts Review (OCTIPER) symposium in Toronto, Canada on August 23rd.
About Bioptigen and Bioptigen's FDA Clearance
Deployed in top ophthalmic research and clinical institutions worldwide, Bioptigen devices are covered by 60- plus patent applications, including 40 awarded patents. More than 300 scientific articles have been published citing data acquired with Bioptigen technologies. Learn more about Bioptigen and its technologies at www.bioptigen.com.
